Semaglutide vs Tirzepatide vs Retatrutide: One, Two and Three Receptors
Semaglutide, tirzepatide and retatrutide are the three most-studied compounds in incretin research, and they form a clear progression: one receptor, then two, then three. Understanding that progression is the key to choosing between them, and to designing studies that separate what each receptor contributes.
At a glance
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Receptors activated | GLP-1 | GIP + GLP-1 | GIP + GLP-1 + glucagon |
| Class | Single (mono-) agonist | Dual agonist | Triple agonist |
| Peptide backbone | GLP-1 analogue | GIP-based, engineered for GLP-1 activity | Engineered for activity at all three receptors |
| Half-life extension | C18 fatty diacid (albumin binding) | C20 fatty diacid (albumin binding) | Fatty diacid (albumin binding) |
| Main research uses | GLP-1 receptor signaling, beta-cell models | GIP/GLP-1 interaction, biased signaling | Adding glucagon signaling; hepatic and energy-expenditure models |
The three receptors in one paragraph each
GLP-1 receptor. Activated by glucagon-like peptide-1, released from the gut after nutrient intake. In research models it drives glucose-dependent insulin secretion and is linked to satiety signaling in the brain.
GIP receptor. Activated by glucose-dependent insulinotropic polypeptide, the other main incretin hormone. It also stimulates insulin secretion and is expressed in adipose tissue, which makes its role in energy storage an active research area.
Glucagon receptor. Glucagon normally raises blood glucose, but it also acts on liver fat metabolism and energy expenditure. Combining glucagon activity with the incretins is studied as a way to add those hepatic and energy effects.
Semaglutide: the single-receptor reference
Semaglutide activates only the GLP-1 receptor. An amino-acid substitution protects it from the enzyme DPP-4, and its fatty-acid side chain binds albumin, together giving it a far longer half-life than native GLP-1. Because it isolates one receptor, it is the natural control arm when studying multi-agonists. Semaglutide research profile.
Tirzepatide: two receptors, deliberately unbalanced
Tirzepatide is built on a GIP backbone and engineered to also activate the GLP-1 receptor. It is imbalanced by design, with stronger activity at the GIP receptor. Researchers use it to study how the two incretin pathways interact, and to explore biased signaling, where a compound favors some intracellular pathways over others at the same receptor. Tirzepatide research profile.
Retatrutide: adding glucagon
Retatrutide activates GIP, GLP-1 and glucagon receptors. The glucagon component is what sets it apart, and it is the reason retatrutide is studied in liver-fat and energy-expenditure models where the incretins alone have less effect. Retatrutide research profile.
Designing a comparison study
Because each compound adds one receptor to the last, the three form a natural panel:
- Semaglutide vs tirzepatide isolates what GIP agonism adds.
- Tirzepatide vs retatrutide isolates what glucagon agonism adds.
- Semaglutide + cagrilintide tests a different combination: GLP-1 with amylin, a separate receptor family.
Handling notes
All three are long, acylated peptides supplied as lyophilized powder. Store sealed vials at -20°C away from light, let them reach room temperature before opening, and avoid repeated freeze-thaw cycles once in solution. Our peptide storage guide covers the details.
Every lot we sell is tested by Bioviridian Labs (ISO/IEC 17025, Texas) for HPLC purity, mass-spectrometry identity, endotoxin and heavy metals. Mass spec matters here: these compounds are close in size, and identity testing confirms the vial holds the molecule on the label.
Shop metabolic research compounds →
For laboratory research use only. Not for human or veterinary use. This article summarizes receptor pharmacology and published research for educational purposes and does not provide medical advice.